QT Prolongation Risk Assessment in Oncology: Lessons Learned From Small‐Molecule New Drug Applications Approved During 2011‐2019 von Cohen‐Rabbie, Sarit, Berges, Alienor C., Rekić, Dinko, Parkinson, Joanna, Dota, Corina, Tomkinson, Helen K.

Volltext

An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers von Tomkinson, Helen K., BSc Hons, MSc, Kemp, John V., HNC, Wollseifen, Thomas, Dipl-Inform, Morris, Thomas, MRCP, Oliver, Stuart D., MFPM

Volltext

A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors von LoRusso, Patricia M, Infante, Jeffrey R, Kim, Kevin B, Burris, 3rd, Howard A, Curt, Gregory, Emeribe, Ugochi, Clemett, Delyth, Tomkinson, Helen K, Cohen, Roger B

Volltext

A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors von Infante, Jeffrey R., Cohen, Roger B., Kim, Kevin B., Burris, Howard A., Curt, Gregory, Emeribe, Ugochi, Clemett, Delyth, Tomkinson, Helen K., LoRusso, Patricia M.

Volltext

Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors von Infante, Jeffrey R., Cohen, Roger B., Kim, Kevin B., Burris, Howard A., Curt, Gregory, Emeribe, Ugochi, Clemett, Delyth, Tomkinson, Helen K., LoRusso, Patricia M.

Volltext